Literature DB >> 9117255

Autologous transplantation of blood stem cells mobilized with filgrastim alone in 93 patients with malignancies: the number of CD34+ cells reinfused is the only factor predicting both granulocyte and platelet recovery.

C Faucher1, A G Le Corroller, C Chabannon, P Viens, A M Stoppa, R Bouabdallah, J Camerlo, N Vey, G Gravis, J A Gastaut, G Novakovitch, P Mannoni, V J Bardou, J P Moatti, D Maraninchi, D Blaise.   

Abstract

High-dose chemotherapy (HDC) supported by autologous transplantation of blood stem cells (BSC) is used increasingly for patients with poor-risk malignancies. We report our experience with 93 consecutive patients who were mobilized with recombinant human granulocyte colony-stimulating factor (rhG-CSF) alone. They received a fixed dose of G-CSF for 5 or 6 days, and BSC were collected by leukapheresis. Aphereses were evaluated for MNC, CD34+ cells, and CFU-GM counts and cryopreserved. All patients received a conditioning regimen without TBI. Engraftment was assessed as the first of 2 consecutive days on which patients achieved 0.5 and 1 x 10(9)/L neutrophils and an unsupported platelet count of 25 x 10(9)/L. Multivariate analysis was performed to study patients and graft characteristics that could influence reconstitution. The G-CSF priming regimen was well tolerated and allowed collection of BSC for all patients, 66% of them achieving >3 x 10(6)/kg CD34+ cells, and 86% achieving >10 x 10(4) CFU-GM/kg. The numbers of collected CD34 and CFU-GM cells were highly correlated. The number of courses of chemotherapy prior to collection, a diagnosis of breast cancer, the use of rhG-CSF posttransplant, and the numbers of CFU-GM and CD34+ cells reinfused were correlated with hematologic recovery. In a multivariate analysis, however, the number of CD34+ cells was the only factor independently influencing both granulocyte and platelet recovery. Patients who received at least 3 x 10(6)/kg CD34+ cells achieved granulocyte reconstitution on day 11 after reinfusion (range 8-15) and an unsupported platelet count of 25 x 10(9)/l on day 14 (range 12-180), significantly earlier than patients who received fewer cells (p < 0.001). In addition, G-CSF administration postreinfusion independently enhanced granulocyte reconstitution but not platelet recovery. In conclusion, CD34+ cell number appears to be the only factor predicting both granulocyte and platelet reconstitution. Based on this study, the collection of a minimal number of 3 x 10(6)/kg CD34+ cells appears desirable.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9117255     DOI: 10.1089/scd.1.1996.5.663

Source DB:  PubMed          Journal:  J Hematother        ISSN: 1061-6128


  5 in total

1.  Amyloid deposits in the bone marrow of patients with immunoglobulin light chain amyloidosis do not impact stem cell mobilization or engraftment.

Authors:  Andrew J Cowan; David C Seldin; Martha Skinner; Karen Quillen; Gheorghe Doros; Josenia Tan; Carl O'Hara; Kathleen T Finn; Vaishali Sanchorawala
Journal:  Biol Blood Marrow Transplant       Date:  2012-07-27       Impact factor: 5.742

2.  Mobilization of hematopoietic progenitor cells with granulocyte colony stimulating factors for autologous transplant in hematologic malignancies: a single center experience.

Authors:  Raul Gabús; Gabriel Borelli; Martín Ferrando; Enrique Bódega; Estela Citrín; Constanza Olivera Jiménez; Ramón Alvarez
Journal:  Rev Bras Hematol Hemoter       Date:  2011

3.  Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation.

Authors:  C P Schröder; G B Wisman; S de Jong; W T van der Graaf; M H Ruiters; N H Mulder; L F de Leij; A G van der Zee; E G de Vries
Journal:  Br J Cancer       Date:  2001-05-18       Impact factor: 7.640

4.  Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone.

Authors:  A D Sung; D T Grima; L M Bernard; S Brown; G Carrum; L Holmberg; M E Horwitz; J L Liesveld; J Kanda; B McClune; P Shaughnessy; G J Tricot; N J Chao
Journal:  Bone Marrow Transplant       Date:  2013-06-10       Impact factor: 5.483

5.  High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: a randomized multicentre study.

Authors:  C Chabannon; K Cornetta; J P Lotz; C Rosenfeld; M Shlomchik; S Yanovitch; J P Marolleau; G Sledge; G Novakovitch; E F Srour; B Burtness; J Camerlo; G Gravis; J Lee-Fischer; C Faucher; I Chabbert; D Krause; D Maraninchi; B Mills; L Kunkel; F Oldham; D Blaise; P Viens
Journal:  Br J Cancer       Date:  1998-10       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.